Adolor Corporation Provides Update on Entereg(R) (alvimopan) OBD Program

July 3, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (Nasdaq: ADLR) today issued an update on the Entereg® (alvimopan) Program for chronic opioid bowel dysfunction (OBD), under development in collaboration with GlaxoSmithKline (NYSE: GSK).

Twitter
LinkedIn
Facebook
Email
Print

GlaxoSmithKline